Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New checkpoint inhibitors ride the immunotherapy tsunami.

× No keyword cloud information.

32 in total

1. 2014 FDA drug approvals.

Authors: Asher Mullard
Journal: Nat Rev Drug Discov Date: 2015-02 Impact factor: 84.694

2. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.

Authors: Arutselvan Natarajan; Aaron T Mayer; Robert E Reeves; Claude M Nagamine; Sanjiv Sam Gambhir
Journal: Mol Imaging Biol Date: 2017-12 Impact factor: 3.488

3. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.

Authors: A Ray; D S Das; Y Song; P Richardson; N C Munshi; D Chauhan; K C Anderson
Journal: Leukemia Date: 2015-01-30 Impact factor: 11.528

Review 4. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Authors: Gregory T Wurz; Chiao-Jung Kao; Michael W DeGregorio
Journal: Ther Adv Med Oncol Date: 2016-01 Impact factor: 8.168

Review 5. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors: Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2017-08-30 Impact factor: 8.110

6. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.

Authors: Xiuyun Lin; Tao Zeng; Jinxiang Lin; Qiong Zhang; Haoling Cheng; Shubin Fang; Shuchun Lin; Yuanzhong Chen; Yunlu Xu; Jizhen Lin
Journal: Cancer Biol Ther Date: 2019-11-06 Impact factor: 4.742

New checkpoint inhibitors ride the immunotherapy tsunami.

1. 2014 FDA drug approvals.

2. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.

3. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.

Review 4. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Review 5. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

6. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.

Review 7. Targeting the PD-1 pathway: a promising future for the treatment of melanoma.

8. Induction of HLA-A*33-restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH.

9. Biomimetic Nanoparticle Vaccines for Cancer Therapy.

10. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.